SCHEMBL15436008

SCHEMBL15436008

Cc1ccc(C(=O)c2cnc(N[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)s2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
SLC5A2 P31639 1/20 0.45
GRK6 P43250 2/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
PRNP P04156 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 1/20 0.41
CFTR P13569 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15445202 1.00 TSHR (0.50) TSHRSLC5A2GRK6NPC1RAB9A
SCHEMBL15436009 1.00 TSHR (0.50) TSHRSLC5A2GRK6NPC1RAB9A
SCHEMBL16946203 1.00 TSHR (0.50) TSHRSLC5A2GRK6NPC1RAB9A
SCHEMBL15445173 1.00 TSHR (0.50) TSHRSLC5A2GRK6NPC1RAB9A
SCHEMBL15436093 0.90 SMN1; SMN2 (0.53) TSHRNPC1RAB9ASMN1; SMN2PRNP
SCHEMBL15436094 0.90 SMN1; SMN2 (0.53) TSHRNPC1RAB9ASMN1; SMN2PRNP
SCHEMBL16941684 0.90 SMN1; SMN2 (0.53) TSHRNPC1RAB9ASMN1; SMN2PRNP
SCHEMBL16941643 0.90 SMN1; SMN2 (0.53) TSHRNPC1RAB9ASMN1; SMN2PRNP
SCHEMBL15436030 0.89 NPC1 (0.51) TSHRNPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL16946197 0.89 NPC1 (0.51) TSHRNPC1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900678-B1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG CENTRE NAT RECH SCIENT (FR) 2020-09-02 EP disclosed
US-10273313-B2 Multimeric mannosides, a process for preparing the same and their uses as a drug CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-04-30 US disclosed
EP-2900678-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2015-08-05 EP disclosed
US-20150210781-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG NANTES UNIVERSITE (FR) 2015-07-30 US disclosed
WO-2014016361-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-01-30 WO disclosed
EP-2690105-A1 Mannose derivatives, a process for preparing the same and their uses as a drug Centre National De La Recherche Scientifique (FR) 2014-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273313-B2 Multimeric mannosides, a process for preparing the same and their uses as a drug MANBA, MAN2A1, MAN2B2 TSHR 4747/4885SLC5A2 479/4885GRK6 1614/4885
US-20150210781-A1 MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG MANBA, MAN2A1, MAN2B2 TSHR 4747/4885SLC5A2 479/4885GRK6 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.